ADC Therapeutics is up 10.6%, or 47c to $4.91.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT:
- ADC Therapeutics Showcases Cancer Treatment Innovations
- ADC Therapeutics completes dose escalation in LOTIS-7 to treat r/r B-NHL
- ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
- ADC Therapeutics initiated with a Buy at Guggenheim